7-hydroxystaurosporine has been researched along with Neoplasms in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 24 (80.00) | 29.6817 |
| 2010's | 5 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asami, Y; Crump, A; Ōmura, S | 1 |
| Huang, RC; Kimura, K | 1 |
| Giordano, A; Lapenna, S | 1 |
| Kuntz, K; O'Connell, MJ | 1 |
| Demidenko, E; Eastman, A; Hou, H; Khan, N; Lariviere, JP; Mupparaju, SP; Swartz, HM | 1 |
| Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA | 1 |
| Bartek, J; Hasvold, G; Lukas, J; Petersen, L; Syljuåsen, RG | 1 |
| Adkins, DR; Arquette, MA; Cai, SR; Chen, RC; Creekmore, AN; Dancey, J; Ellis, MJ; Fleshman, JW; Fracasso, PM; Goodner, SA; Guo, Z; Lin, L; Ma, CX; McLeod, HL; Naughton, MJ; Picus, J; Piwnica-Worms, H; Pluard, TJ; Rader, JS; Rudek, MA; Ryan, CE; Soares, EM; Tan, BR; Tao, Y; Williams, KJ; Wright, LP | 1 |
| Senderowicz, AM | 4 |
| Swanton, C | 1 |
| Lam, MH; Rosen, JM | 1 |
| Cao, P; Gronda, M; Hedley, DW; Jacobberger, JW; Pham, NA; Schimmer, AD | 1 |
| Acharya, MR; Chen, H; Figg, WD; Headlee, D; Kuwabara, T; Messmann, RA; Murgo, AJ; Sausville, EA; Senderowicz, AM; Sparreboom, A; Venzon, DJ | 1 |
| Sausville, EA | 1 |
| Gonen, M; Ilson, DI; Kaubisch, A; Kelsen, DP; Kemeny, N; Kortmansky, J; Maki, RG; O'reilly, E; Saltz, LB; Schwartz, GK; Shah, MA; Sowers, R; Tong, W; Weyerbacher, A; Yi, S | 1 |
| Aylesworth, C; Baker, SD; Carducci, MA; Davidson, SB; Dees, EC; Donehower, RC; Elza-Brown, K; O'Reilly, S; Rudek, MA | 1 |
| Blagden, S; de Bono, J | 1 |
| Doroshow, JH; Frankel, P; Gandara, DR; Gumerlock, PH; Lara, PN; Longmate, J; Mack, PC; Synold, T | 1 |
| Baras, A; Chua, A; Maxhimer, JB; Nguyen, DM; Schrump, DS; Shamimi-Noori, S; Yeow, WS; Ziauddin, MF | 1 |
| Beaulieu, B; Beelen, AP; Eastman, A; Ernstoff, MS; Johnston, N; Lewis, LD; Olszanski, AJ; Perez, RP; Rhodes, CH | 1 |
| Baker, SD; Carducci, MA; Dancey, J; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, DA; Messersmith, WA; Purcell, T; Rudek, MA | 1 |
| Bauer, KS; Bisacia, S; Dancey, J; Edelman, MJ; Smith, R; Wu, S | 1 |
| Chen, XG; Zuo, MX | 1 |
| Eastman, A; Fanous, AA; Levesque, AA; Poh, A | 1 |
| Blume, E | 1 |
| Sausville, EA; Senderowicz, AM | 1 |
| Arbuck, SG; Bauer, KS; Figg, WD; Fuse, E; Headlee, D; Jaken, S; Jing , X; Kuwabara, T; Lahusen, T; Lush, RM; Messmann, R; Murgo, A; Roberge, M; Sausville, EA; Senderowicz, AM | 1 |
12 review(s) available for 7-hydroxystaurosporine and Neoplasms
| Article | Year |
|---|---|
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine | 2018 |
Cell cycle kinases as therapeutic targets for cancer.
Topics: Animals; Aurora Kinases; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinases; DNA Damage; Humans; Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Retinoblastoma-Like Protein p130; Staurosporine | 2009 |
The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer?
Topics: Antineoplastic Agents; Biological Evolution; Cell Cycle Proteins; Checkpoint Kinase 1; Conserved Sequence; DNA Damage; DNA, Neoplasm; DNA, Single-Stranded; Drug Delivery Systems; G2 Phase; Genes, cdc; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Replication Protein A; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Species Specificity; Staurosporine | 2009 |
The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine | 2002 |
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Clinical Trials, Phase I as Topic; Cyclin-Dependent Kinases; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Flavonoids; Humans; Neoplasm Proteins; Neoplasms; Piperidines; Signal Transduction; Staurosporine; Transcription, Genetic | 2002 |
Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine; Tumor Cells, Cultured | 2003 |
Cell-cycle targeted therapies.
Topics: Animals; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine | 2004 |
Chk1 versus Cdc25: chking one's levels of cellular proliferation.
Topics: Animals; Antineoplastic Agents; cdc25 Phosphatases; Cell Cycle Proteins; Cell Proliferation; Checkpoint Kinase 1; Clinical Trials as Topic; Humans; Mice; Models, Biological; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Staurosporine | 2004 |
Drugging cell cycle kinases in cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles | 2005 |
Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Piperidines; Protein Kinase Inhibitors; Staurosporine | 2005 |
[Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinases; Cyclins; Flavonoids; Humans; Neoplasms; Piperidines; Purines; Roscovitine; Staurosporine | 2007 |
Preclinical and clinical development of cyclin-dependent kinase modulators.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinases; Enzyme Inhibitors; Flavonoids; Humans; Neoplasms; Piperidines; Staurosporine | 2000 |
10 trial(s) available for 7-hydroxystaurosporine and Neoplasms
| Article | Year |
|---|---|
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prednisone; Staurosporine; Young Adult | 2010 |
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Young Adult | 2011 |
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Topics: Antineoplastic Agents; Female; Half-Life; Humans; Infusions, Intravenous; Male; Neoplasms; Orosomucoid; Staurosporine | 2004 |
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Female; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Staurosporine; Treatment Outcome | 2005 |
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase C; Salvage Therapy; Staurosporine; Time Factors | 2005 |
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrial Fibrillation; Blotting, Western; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Cyclin B; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Deglutition Disorders; Dose-Response Relationship, Drug; Female; Humans; Hyponatremia; Infections; Male; Middle Aged; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Renal Insufficiency; Staurosporine; Tachycardia; Treatment Outcome; Tumor Suppressor Proteins | 2005 |
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cell Cycle; Cisplatin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Injections, Intravenous; Maximum Tolerated Dose; Neoplasms; Predictive Value of Tests; Staurosporine; Tissue Distribution; Treatment Outcome | 2006 |
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Staurosporine; Topoisomerase I Inhibitors | 2008 |
Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Synergism; Female; Humans; Male; Middle Aged; Neoplasms; Staurosporine | 2007 |
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting | 2001 |
8 other study(ies) available for 7-hydroxystaurosporine and Neoplasms
| Article | Year |
|---|---|
Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01.
Topics: Antineoplastic Agents; Autophagy; Carbohydrate Metabolism; Caspase 7; Cell Line, Tumor; Down-Regulation; Drug Synergism; Energy Metabolism; Etoposide; Glutathione; Humans; Lipid Metabolism; Male; Masoprocol; Metabolic Networks and Pathways; Metabolome; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sirolimus; Staurosporine | 2016 |
Radiotherapy in conjunction with 7-hydroxystaurosporine: a multimodal approach with tumor pO2 as a potential marker of therapeutic response.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Electron Spin Resonance Spectroscopy; Female; Mice; Mice, Inbred C3H; Neoplasms; Oxygen; Staurosporine | 2009 |
p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors.
Topics: Cell Cycle; Cell Death; Cell Survival; Checkpoint Kinase 1; Colonic Neoplasms; Genes, p53; HCT116 Cells; Humans; Neoplasms; Nervous System Neoplasms; Protein Kinases; Radiation, Ionizing; Staurosporine; Tumor Suppressor Protein p53 | 2010 |
The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice.
Topics: Animals; Anticarcinogenic Agents; Antigens; Apoptosis; Blotting, Western; Caspase 3; Caspase 8; Caspases; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Nucleus; DNA; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Glutathione; Humans; Isothiocyanates; Male; Membrane Potentials; Mice; Mice, SCID; Microscopy, Fluorescence; Mitochondria; Mitosis; Neoplasm Transplantation; Neoplasms; Oxidative Stress; Pancreatic Neoplasms; Reactive Oxygen Species; Staurosporine; Sulfoxides; Thiocyanates; Time Factors; Tyrosine | 2004 |
Indifferently pursued or unowned drugs: who should lead where companies do not tread?
Topics: Antineoplastic Agents; Drug Industry; Humans; Neoplasms; Orphan Drug Production; Protein Kinase Inhibitors; Staurosporine | 2005 |
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Topics: Anticonvulsants; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Neoplasms; NF-kappa B; Staurosporine; Tumor Cells, Cultured; Valproic Acid | 2006 |
Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest.
Topics: Camptothecin; Cell Cycle; Cell Proliferation; Checkpoint Kinase 1; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; G2 Phase; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; S Phase; Signal Transduction; Staurosporine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2008 |
Researchers gain footholds in the cell cycle.
Topics: Alkaloids; Animals; Antineoplastic Agents; Cell Cycle; DNA, Neoplasm; Humans; Neoplasms; Pentoxifylline; Staurosporine | 1995 |